Om

Vivesto AB is a Swedish pharmaceutical company focused on developing a new generation of drugs in human and veterinary oncology. The company’s primary purpose is to create treatment options for cancers that are difficult to treat, addressing unmet medical needs in both human patients and companion animals. Vivesto AB concentrates on research and development activities, leveraging formulation technologies and oncology expertise to enhance the delivery and effectiveness of established and novel anticancer agents. Its portfolio targets a range of solid tumors and hematologic malignancies, positioning the company within the specialized segment of oncology therapeutics. In the veterinary field, Vivesto AB develops cancer treatments tailored to the specific medical and regulatory requirements of animal health. Headquartered in Sweden, Vivesto AB collaborates with industry partners, contract manufacturers, and clinical research organizations to advance its pipeline from preclinical development through clinical studies, aiming to supply hospitals, specialty clinics, and veterinary practices in key global markets.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I VIVESTO MED ENDAVU: Køb Vivesto ($OMA) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Vivesto, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.